Advantages of Flow Cytometry in Immunotherapy Clinical Trials
Complex flow cytometry is critical for today’s personalized medicine. With 25 years of extensive expertise in providing flow cytometry testing for clinical trials ranging from phase I to phase III, Cerba Research has a strong track record of developing and validating custom-made flow cytometry panels. Monitor immunophenotyping, immune cell activation, receptor occupancy of the drug, and the workings of CAR-T cells through flow cytometry on blood samples and bone marrow aspirate.
Our Global Flow Cytometry Network
At Cerba Research, we develop, validate, qualify and implement assays on a global scale. With flow cytometry capacity and capabilities in Belgium, the United States, Australia, China and Taiwan, we are a leading central lab known for our expertise. Our network develops and validates drug-specific panels aligned with your needs. From client conversations to centralized data analysis and review, our global team is dedicated to meeting your target timeline.
Which Flow Cytometry instruments are present in our laboratories worldwide?
BD FACS Canto: present in laboratories in USA, Belgium, and China
BD FACS Lyrics: present in laboratories in USA, Belgium, Australia, and Taiwan
Cytek Aurora in laboratories in USA and Belgium
Assess more than 40 parameters with the Cytek Aurora
With our spectral flow cytometry capabilities, we simultaneously characterize cellular populations from the same tube with a complete set of data from the sample, all while reducing the time of sample acquisition.
Cerba Research is proud to answer your exploratory needs for clinical trials and retrospective analysis with our state of art instruments and high quality data output.
Tailor-made proprietary/ drug-specific panels
In-house validation and method transfer to other Cerba Research labs
Global acceptance criteria and instrument and assay standardization
CAR+T Drug Development: The Critical Role of Flow Cytometry
Flow cytometry plays a crucial role in the production process of CAR+ T cells, where it is used for assessing transduction efficiency, purity, and characterization of the CAR+ T product before infusion. After manufacturing, when CAR+ T cells are infused into the patients, flow cytometry is used again in clinical laboratories to assess CAR+ T expansion, efficiency, and persistence and to monitor minimal residual disease (MRD).
In our CAR+T Drug Developmentebook, Ans De Beuckelaer, Regional Head Flow Cytometry EU, and Rowan Claeys, Clinical Biologist at Cerba Research, dive deeper into key elements of flow cytometry:
The importance of flow cytometry in Car+T clinical research and its uses
Key aspects in developing a CAR+ T trial
The added value of flow cytometry in multiple myeloma, Minimal Residual Disease (MRD) assessments, and multiple myeloma phenotype
Car+T-cell Therapy: patient treatment, targeted antigens and solutions for MRD assessments and multiple myeloma phenotype assessment.